A PhaseII Study of Bevacizumab in Combination with S-1 in Patients with Non-Squamous Non-Small-Cell Lung Cancer reviously treated with platinum based chemotherapy

A PhaseII Study of Bevacizumab in Combination with S-1 in Patients with Non-Squamous Non-Small-Cell Lung Cancer reviously treated with platinum based chemotherapy - A PhaseII Study of Bevacizumab in Combination with S-1 in Patients with Non-Squamous Non-Small-Cell Lung Cancer reviously treated with platinum based chemotherapy

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005486

Enrollment

Registered

2011-04-22

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Squamous Non-Small-Cell Lung Cancer

Interventions

S-1: 40 mg/m2 twice daily(orally, day1 after dinner

day15 after breakfast) Bevacizumab: 15mg/kg day 1 The treatment is repeated every three weeks until disease progression or severe toxicity.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Histologically proven non-squamous non-small cell lung cancer (2) Written informed consent after the explanation of the content of the examination (3) Age:20-74 years old (4) ECOG performance status of 0-1 (5) Life expectancy more than 3 months (6) Adequate organ functions 1.Neutrophil ->2,000 /mm3 2.Platelet -> 100,000 /mm3 3.Hemoglobin concentration -> 9.0 g/dl 4.Total bilirubin <- 1.5 mg/dl 5.AST or ALT <- 100IU/l 6.Cr <= 1.5 mg/dl

Exclusion criteria

Exclusion criteria: (1) Previously untreated with platinum doublet (2) transfusion or G-CSF within 2weeks prior to enrollment (3) Severe renal function disorder, 2+ or higher proteinuria within 2 weeks prior to enrollment (4) History of severe drug allergy (5) History of active double cancer within 5 years (6) History of active severe infections (7) Patients who have fever of over 38 degrees (8) Continuous administration of steroid drug (9) Severe cardiac disease (10) History of thromboembolism or severe pulmonary disease (11) History of GI bleeding,ileus,GI ulceration (12) massive pleural or pericardial effusion,ascites (13) Symptomatic brain metastases (14) Uncontrollable hypertension or diabetes mellitus (15) Uncontrollable diarrhea (16) Wound of unrecovery (17) Traumatic fracture of unrecovery (18) bleeding diathesis or receiving anticoagulant drug(except Aspirin under 324mg/day) (19) History of pregnancy or lactation (20) Evaluated to be ineligible by a physician for other reasons

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
progression free survival,time to treatment failur,overall survival,and safety	—

Countries

Japan

Contacts

Public ContactYasuo Iwamoto

Hiroshima citizens hospital Department of Medical Oncology

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026